Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.
Capstan Therapeutics has raised $175.0M in total funding. The most recent round was Series B. The last funding was announced in March 2024.
Capstan Therapeutics's investors include RA Capital Management, Perceptive Advisors, Vida Ventures, Polaris Partners, OrbiMed.
Capstan Therapeutics is headquartered in San Diego, United States.
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.
Capstan Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Capstan Therapeutics — Funding & Investors." VCBacked, March 20, 2024, https://www.vcbacked.co/company/capstan-therapeutics. Accessed November 13, 2026.
VCBacked. (2024). Capstan Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/capstan-therapeutics
{{cite web |title=Capstan Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/capstan-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Capstan Therapeutics? Request a listing update